WAVE Life Sciences Ltd. (NASDAQ:WVE) is reporting third quarter earnings results on Monday 9th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.69 per share.
For the full year, analysts predict revenues of $ 31.07 million, while looking forward to loss of $ 3.66 per share.
Previous Quarter Performance
WAVE Life Sciences Ltd. recorded loss for the second quarter of $ 1.15 per share, from the revenue of $ 3.03 million. The quarterly revenues reduced 60.29 percent compared with the same quarter last year. According to street consensus, WVE was expected to report 2Q20 loss of $ 0.97 per share from revenue of $ 5.65 million. The bottom line results missed street analysts by $ 0.18 or 18.56 percent, at the same time, top line results fell short of analysts by $ 2.62 million or 46.37 percent.
Stock Performance
On Friday, shares of WAVE Life Sciences Ltd. has traded high as $ 7.39 and has cracked $ 7.06 on the downward trend, reaching $ 7.22 with volume of 435.80 thousand shares.
According to the previous trading day, closing price of $ 7.22, representing a 9.98 % increase from the 52 week low of $ 6.61 and a 81.82 % decrease over the 52 week high of $ 39.98.
The company has a market capital of $ 349.92 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
WAVE Life Sciences Ltd. will be hosting a conference call at 8:30 AM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.wavelifesciences.com
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system.
